Clinical Practice Guideline on Benzodiazepine Tapering
SUMMARY:
Benzodiazepines (BZDs) are FDA-approved medications frequently prescribed for anxiety disorders, panic disorders, social phobia, insomnia, and seizures. As patients age or as their health status and other medications change, the risk–benefit ratio of continued benzodiazepine use may shift. Physical dependence is an expected consequence of regular use, and discontinuing BZDs can be challenging. Abruptly stopping BZDs or reducing the dose too quickly can result in serious and potentially life-threatening withdrawal symptoms.
Benzodiazepine tapering is a patient-centered, gradual process for discontinuing medications associated with dependence, withdrawal risk, and significant harms e.g., increased likelihood of falls, motor vehicle accidents, cognitive impairment, delirium, overdose, death when used long-term. Tapering is indicated when risks outweigh benefits, with abrupt discontinuation strongly discouraged due to the risk of withdrawal and serious adverse events. The 2025 Joint Clinical Practice Guidelines on Benzodiazepine Tapering developed by ASAM and 9 other medical and professional societies advises individualizing the pace and duration of the taper to optimize safety and minimize withdrawal symptoms.
Key Considerations
- Clinicians should regularly reassess benzodiazepine use, ideally at least every 3 months, to weigh ongoing risks and benefits.
- Review prescription drug monitoring programs for all benzodiazepine renewals or new prescriptions.
Evaluate for physical dependence | duration and dosage | SUD | psychiatric or medical comorbidities e.g., OSA, COPD
- Do not abruptly discontinue in physically dependent patients; assess for special circumstances requiring referral (substance misuse, high doses, or unstable conditions)
- Assess for signs of benzodiazepine dependence and withdrawal risk—patients with prolonged| high-dose use| comorbidities e.g., need slower, monitored tapers.
- Identify patients with co-occurring substance use disorders, as these individuals may require coordinated care, harm reduction, and possibly higher levels of medical supervision.
- Differential includes differentiating between withdrawal symptoms, recurrence of original anxiety or insomnia symptoms, and acute psychiatric or medical conditions
- Engage patients collaboratively in their taper plan to enhance adherence and safety
Implementing Deprescribing
- First-line: gradual dose reduction by 5–10% every 2–4 weeks, not exceeding 25% in any 2-week period; personalize based on patient response
- Those on lower doses for less than 3 months may taper more rapidly, while patients with longer or higher-dose exposure may need months or years to complete a taper
- Switching to a longer-acting benzodiazepine is not routinely necessary and should only be considered if needed for dose manipulation or patient comfort
- Monitor for withdrawal symptoms during each dose reduction; pause or slow tapers as needed to maintain safety.
- For Z-drugs (zolpidem, zopiclone), use a similar approach; both short- and long-term users are at risk for withdrawal.
- Adjunctive strategies may include psychosocial interventions, cognitive-behavioral therapy, and addressing co-occurring psychiatric or substance use disorders.
- Refer for specialist support or a higher level of care when complications or safety concerns arise.
Follow Up
- Reassess withdrawal symptoms, mental and physical health, and overall progress at every tapering visit, with frequency based on clinical risk and phase of taper.
- Engage patients in assessing readiness for further dose reduction or need to pause the taper.
- Provide ongoing support, education on harm reduction, and access to adjunctive therapies for withdrawal or relapse prevention.
KEY POINTS
- Tapering benzodiazepines requires gradual, individualized reductions, with 5–10% dose decreases every 2–4 weeks favored as standard practice
- Clinicians must not abruptly discontinue benzodiazepines in physically dependent individuals and should monitor closely for withdrawal
- Patient engagement and shared decision-making are essential for successful outcomes
- Specialist referral is recommended for complex cases (substance use disorder, high-dose use, adverse withdrawal) or treatment difficulty
- The overall goal is improved safety, reduced harm, and restoration of patient quality of life
